Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium Infections | 21 | 2024 | 56 | 3.910 |
Why?
|
| Ribotyping | 13 | 2021 | 26 | 2.070 |
Why?
|
| Anti-Bacterial Agents | 17 | 2025 | 183 | 1.410 |
Why?
|
| Feces | 7 | 2025 | 26 | 1.180 |
Why?
|
| Environmental Microbiology | 3 | 2019 | 9 | 1.070 |
Why?
|
| Cross Infection | 7 | 2021 | 19 | 0.920 |
Why?
|
| Bacterial Toxins | 8 | 2024 | 16 | 0.880 |
Why?
|
| Diarrhea | 2 | 2019 | 23 | 0.730 |
Why?
|
| Spores, Bacterial | 3 | 2021 | 24 | 0.630 |
Why?
|
| Dog Diseases | 1 | 2019 | 3 | 0.620 |
Why?
|
| Animals, Zoo | 1 | 2019 | 3 | 0.620 |
Why?
|
| Polymerase Chain Reaction | 6 | 2020 | 38 | 0.610 |
Why?
|
| Humans | 29 | 2025 | 5477 | 0.530 |
Why?
|
| Vancomycin | 7 | 2025 | 28 | 0.520 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2024 | 99 | 0.480 |
Why?
|
| Family Characteristics | 1 | 2014 | 17 | 0.420 |
Why?
|
| Tetracyclines | 3 | 2025 | 15 | 0.310 |
Why?
|
| Cell Wall | 2 | 2021 | 13 | 0.300 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2022 | 34 | 0.270 |
Why?
|
| Molecular Epidemiology | 4 | 2020 | 7 | 0.260 |
Why?
|
| Urban Population | 2 | 2019 | 18 | 0.260 |
Why?
|
| Middle Aged | 9 | 2025 | 1098 | 0.240 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 136 | 0.240 |
Why?
|
| Bangladesh | 3 | 2022 | 6 | 0.240 |
Why?
|
| Texas | 5 | 2020 | 190 | 0.230 |
Why?
|
| Female | 11 | 2025 | 2811 | 0.230 |
Why?
|
| Fatty Acids, Volatile | 1 | 2025 | 5 | 0.230 |
Why?
|
| Bile Acids and Salts | 1 | 2025 | 9 | 0.230 |
Why?
|
| Male | 11 | 2025 | 2765 | 0.220 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2024 | 20 | 0.220 |
Why?
|
| Purine Nucleosides | 1 | 2024 | 3 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2024 | 15 | 0.210 |
Why?
|
| Pyridines | 3 | 2023 | 24 | 0.200 |
Why?
|
| Candidemia | 2 | 2013 | 9 | 0.200 |
Why?
|
| Candida | 2 | 2013 | 13 | 0.200 |
Why?
|
| Fusobacterium Infections | 1 | 2022 | 3 | 0.200 |
Why?
|
| Fusobacteria | 1 | 2022 | 3 | 0.200 |
Why?
|
| Lipopeptides | 3 | 2017 | 9 | 0.190 |
Why?
|
| Peptides, Cyclic | 3 | 2017 | 9 | 0.190 |
Why?
|
| Aminoglycosides | 3 | 2017 | 17 | 0.190 |
Why?
|
| Hospitals | 2 | 2019 | 10 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 19 | 0.180 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 2 | 0.180 |
Why?
|
| Genotype | 1 | 2021 | 58 | 0.180 |
Why?
|
| Bacterial Proteins | 2 | 2024 | 58 | 0.170 |
Why?
|
| Oxazolidinones | 2 | 2017 | 6 | 0.170 |
Why?
|
| Microbiota | 1 | 2020 | 18 | 0.160 |
Why?
|
| Aged | 6 | 2021 | 859 | 0.160 |
Why?
|
| Disinfectants | 1 | 2019 | 3 | 0.160 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 6 | 0.150 |
Why?
|
| Benzimidazoles | 2 | 2017 | 10 | 0.150 |
Why?
|
| Dogs | 1 | 2019 | 17 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2019 | 17 | 0.150 |
Why?
|
| Metronidazole | 4 | 2024 | 15 | 0.150 |
Why?
|
| Adult | 6 | 2025 | 1683 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 12 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 320 | 0.150 |
Why?
|
| Prevalence | 2 | 2020 | 72 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2018 | 4 | 0.140 |
Why?
|
| Gram-Positive Bacteria | 1 | 2018 | 3 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 3 | 0.140 |
Why?
|
| Biofilms | 2 | 2019 | 27 | 0.130 |
Why?
|
| Enterotoxins | 1 | 2016 | 2 | 0.130 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2017 | 37 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2016 | 18 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 20 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 382 | 0.100 |
Why?
|
| Healthy Volunteers | 2 | 2025 | 42 | 0.100 |
Why?
|
| Amphotericin B | 1 | 2012 | 2 | 0.100 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 5 | 0.100 |
Why?
|
| Animals | 1 | 2019 | 1817 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2012 | 18 | 0.100 |
Why?
|
| Esomeprazole | 1 | 2012 | 1 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 20 | 0.090 |
Why?
|
| Long-Term Care | 2 | 2018 | 5 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 19 | 0.070 |
Why?
|
| Colony Count, Microbial | 2 | 2019 | 13 | 0.070 |
Why?
|
| Caco-2 Cells | 2 | 2016 | 21 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 350 | 0.060 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2025 | 4 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 2024 | 10 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 38 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 212 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2025 | 68 | 0.050 |
Why?
|
| Anaerobiosis | 1 | 2022 | 6 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 6 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 20 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 8 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2021 | 9 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 7 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 59 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 38 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2022 | 112 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 52 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 20 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2021 | 36 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 34 | 0.040 |
Why?
|
| Young Adult | 1 | 2025 | 850 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 35 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 53 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 52 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 80 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 2020 | 3 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2019 | 2 | 0.040 |
Why?
|
| o-Phthalaldehyde | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sodium Hypochlorite | 1 | 2019 | 3 | 0.040 |
Why?
|
| Disinfection | 1 | 2019 | 4 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 16 | 0.040 |
Why?
|
| Biomass | 1 | 2019 | 21 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 137 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 2 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2019 | 2 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 7 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 11 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 33 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 31 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 26 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2018 | 4 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risk Factors | 1 | 2019 | 184 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2017 | 1 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2017 | 2 | 0.030 |
Why?
|
| Thiazoles | 1 | 2017 | 4 | 0.030 |
Why?
|
| Veterans | 1 | 2017 | 24 | 0.030 |
Why?
|
| Depsipeptides | 1 | 2017 | 3 | 0.030 |
Why?
|
| Benzopyrans | 1 | 2017 | 11 | 0.030 |
Why?
|
| Thiophenes | 1 | 2017 | 6 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 131 | 0.030 |
Why?
|
| Fluorescence | 1 | 2016 | 14 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Agar | 1 | 2016 | 5 | 0.030 |
Why?
|
| Culture Media | 1 | 2016 | 18 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 37 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 31 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 119 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 175 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 69 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 71 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 132 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2012 | 4 | 0.020 |
Why?
|
| Thienamycins | 1 | 2012 | 6 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 34 | 0.020 |
Why?
|